Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Veru Inc. | Zuclomiphene citrate | Hot flashes | Phase 2 | Trial Planned | Oral | Women's Health |
| Viatris Inc. | Low dose estrogen weekly patch (150 mcg norelgestromin and 17.5 mcg ethinyl estradiol) | Contraception | PDUFA | Ongoing | Transdermal | Women's Health |
| Viatris Inc. | MYL-1402O | Avastin (bevacizumab) biosimilar | PDUFA | Withdrawn | Intravenous | Oncology |
| Viatris Inc. | MR-107A-02 | Pain | NDA Filing | Data Released | Intravenous | Non-Opioid Analgesic |
| Viatris Inc. | Nyxol + Low-Dose Pilocarpine Eye Drops - (VEGA-2/VEGA-3) | Presbyopia | Phase 3 | Data Released | Ophthalmic | Opthalmic |
| Viatris Inc. | YUPELRI (revefenacin) - (China trial) | Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Data Released | Inhalation | Respiratory |
| Viatris Inc. | pimecrolimus 0.3% (MR-139) | Blepharitis | Phase 3 | Ongoing | topical | Opthalmic |
| Viatris Inc. | MR-142 - (LYNX-2) | Chronic night driving impairment | Phase 3 | Ongoing | oral | Opthalmic |
